+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Thumbnail Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • March 2025
  • 450 Pages
  • Global
From
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets - Product Thumbnail Image

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

  • Report
  • December 2024
  • 125 Pages
  • Global
From
PI3K Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

PI3K Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 150 Pages
  • Global
From
From
From
From
From
Drug Resistant Epilepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Drug Resistant Epilepsy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Progressive Supranuclear Palsy- Pipeline Insight, 2025 - Product Thumbnail Image

Progressive Supranuclear Palsy- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
From
From
Loading Indicator